MedTrace Logo

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

NCT02387216 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2021-10-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.

Conditions

Interventions

DRUG

MM-121

Investigational, fully human antibody targeting and inhibiting ErbB3

DRUG

Docetaxel

approved chemotherapy treatment for NSCLC

Sponsors & Collaborators

  • Merrimack Pharmaceuticals

    collaborator INDUSTRY

  • Elevation Oncology

    lead INDUSTRY

Principal Investigators

  • MM-121 Program Medical Director, MD · Merrimack Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-01
Primary Completion
2019-01-02
Completion
2019-01-02

Countries

  • United States
  • Canada
  • France
  • Germany
  • Hungary
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02387216 on ClinicalTrials.gov